TD Cowen reiterated a buy rating on MBX Biosciences shares, and Citigroup restated an outperform rating on the company.
7 reports, 2 independent
Updated Mon 00:00
Mostly repetition
- Reports
- 7
- Developments
- 2
- Repetition
- 71%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
TD Cowen reiterated a buy rating on MBX Biosciences shares, and Citigroup restated an outperform rating on the company.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Truist Financial raised its target price on MBX Biosciences stock.1 source
Rating firms TD Cowen and Citigroup issued rating actions on MBX Biosciences shares.1 source
Keep exploring
The entities involved
-
TD Cowen
American investment bank
-
Citigroup
American investment bank and financial services corporation
Related events
- Bio-Techne shares traded on Nasdaq, and TD Cowen reiterated a Buy rating with a $65 price target.
- TD Cowen restated a 'buy' rating on Affiliated Managers Group (AMG) on June 6, 2026.
- Citigroup, Morgan Stanley, and TD Cowen have raised their price targets and upgraded ratings for Royalty Pharma, with filings made public via the SEC.
- TD Cowen issued a buy rating and price target for Dexcom on October 9, 2026.
- TD Cowen provided analyst ratings and price targets for Werner Enterprises, while Citigroup also lifted its price target based on company performance.